safety and pharmacokinetics of MAP0004 in adults in Headache.
-- Delivered over 15 oral and poster presentations related to UDB and
MAP0004 at annual scientific conferences including: American
Academy of Allergy Asthma & Immunology (AAAAI), American Academy
of Neurology (AAN), Respiratory Drug Delivery (RDD), American
Thoracic Society (ATS) and American Headache Society (AHS).
-- Corporate progress
-- Added seasoned industry veterans to the management team and board
of directors, including: Donald J. Kellerman, Pharm.D. to the
position of Senior Vice President, Clinical Development and
Medical Affairs; Marco F. Rosa to the position of Vice President
of Human Resources; and H. Ward Wolff to the board of directors
and audit committee.
-- Secured a $20 million working capital loan to repay the existing
working capital loan and for general corporate purposes.
-- Acquired proprietary drug particle formulation technology from
Telesso Technologies Limited, formerly Eiffel Technologies
"We continue to make progress toward our goal of providing better medicines to patients, with clearly differentiated product benefits for undermet medical needs," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "With two product candidates now in Phase 3 studies, we remain focused on building the team, infrastructure and resources we need to advance MAP Pharmaceuticals through Phase 3 trials, toward commercializing products that address major market opportunities."
Second Quarter and Six Month Financial Results
Research and development expenses for the second quarter and six months
ended June 30, 2008 were $13.0 million and $24.8 million, respectively,
compared to $6.3 million and $10.8 million, res
|SOURCE MAP Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved